

## **Supplemental references**

- S1. Reisin A AP Newswire April 18<sup>th</sup> 2002.
- S2. Warner TD and Mitchell JA 2006 COX isoforms in the cardiovascular system: understanding the activities of nonsteroid anti-inflammatory drugs *Nat Rev Drug Disc* ( in press)
- S3 Reilly IA Doran J Smith B and FitzGerald GA 1986 Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. *Circulation*. **73**(6):1300-9.
- S4. Murphrey LJ et al 2004. Quantification of the major urinary metabolite of PGE<sub>2</sub> by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE<sub>2</sub> synthesis in healthy humans and those with lung cancer. *Anal Biochem* **334**(2):266-75.
- S5. Bell-Parikh LC et al 2003 Biosynthesis of 15-deoxy-delta12,14-PGJ<sub>2</sub> and the ligation of PPARgamma. *J Clin Invest*. **112**(6):945-55.
- S6. Fabre JE et al 2001. Activation of the murine EP3 receptor for PGE<sub>2</sub> inhibits cAMP production and promotes platelet aggregation. *J Clin Invest*. **107**(5):603-10
- S7. Nishizawa EE et al 1975 Prostaglandin D<sub>2</sub> as a potential antithrombotic agent. *Prostaglandins*. **9**(1):109-21.